Details for Patent: 9,925,174
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,925,174 protect, and when does it expire?
Patent 9,925,174 protects PRADAXA and is included in two NDAs.
Protection for PRADAXA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-nine patent family members in thirty-seven countries.
Summary for Patent: 9,925,174
Title: | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-me- thyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Abstract: | The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-met- hyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof. |
Inventor(s): | Brauns; Ulrich (Biberach, DE) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 11/381,890 |
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; |
Drugs Protected by US Patent 9,925,174
Foreign Priority and PCT Information for Patent: 9,925,174
International Family Members for US Patent 9,925,174
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 042861 | See Plans and Pricing | |||
Argentina | 072385 | See Plans and Pricing | |||
Austria | 540943 | See Plans and Pricing | |||
Australia | 2003210400 | See Plans and Pricing | |||
Brazil | 0306559 | See Plans and Pricing | |||
Brazil | PI0306559 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |